New therapeutic strategies for the treatment of acute lymphoblastic leukaemia (original) (raw)

• Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166–178 (2006). A comprehensive review of the central role leukaemia biology and host factors have in the design of effective therapies for ALL.
  Article CAS PubMed Google Scholar
• Oeffinger, K. C. & Hudson, M. M. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J. Clin. 54, 208–236 (2004).
  Article PubMed Google Scholar
• Pui, C. H. et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 349, 640–649 (2003).
  Article PubMed Google Scholar
• Pui, C. H., Relling, M. V. & Downing, J. R. Acute lymphoblastic leukemia. N. Eng. J. Med. 350, 1535–1548 (2004). A review of the pathobiology of ALL, emphasizing results that are likely to have the greatest impact on clinical management in the coming decade.
  Article CAS Google Scholar
• Armstrong, S. A. & Look, A. T. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23, 6306–6315 (2005). Informative review of the signal-transduction pathways in ALL, and the role gene expression has in the classification of ALL and the design of molecularly targeted therapy.
  Article CAS PubMed Google Scholar
• LeBien, T. W. Fates of human B-cell precursors. Blood 96, 9–23 (2000).
  CAS PubMed Google Scholar
• Gill, J. et al. Thymic generation and regeneration. Immunol. Rev. 195, 28–50 (2003).
  Article CAS PubMed Google Scholar
• Pui, C. H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605–615 (1998).
  Article CAS PubMed Google Scholar
• Pui, C. H., Campana, D. & Evans, W. E. Childhood acute lymphoblastic leukaemia — current status and future perspectives. Lancet Oncol. 2, 597–607 (2001).
  Article CAS PubMed Google Scholar
• Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1, 75–87 (2002).
  Article CAS PubMed Google Scholar
• Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1, 133–143 (2002).
  Article CAS PubMed Google Scholar
• Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet. 30, 41–47 (2002).
  Article CAS PubMed Google Scholar
• Haferlach, T. et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106, 1189–1198 (2005).
  Article CAS PubMed Google Scholar
• Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005). This report describes a new, bead-based flow cytometric microRNA-expression-profiling method, and highlights the potential of microRNA in cancer diagnosis.
  Article CAS PubMed Google Scholar
• Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004). A report on the presence of activating mutations in more than 50% of human T-cell ALL, providing a strong rationale for targeted therapies that interfere with NOTCH signalling.
  Article CAS PubMed Google Scholar
• Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell. 2, 103–112 (2002).
  Article CAS PubMed Google Scholar
• Krug, U., Ganser, A. & Koeffler, H. P. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21, 3475–3495 (2002).
  Article CAS PubMed Google Scholar
• Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002).
  Article CAS Google Scholar
• Avramis, V. I. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99, 1986–1994 (2002).
  Article CAS PubMed Google Scholar
• Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P. & Buchanan, G. R. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96, 1709–1715 (2000).
  CAS PubMed Google Scholar
• Hak, L. J. et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072–1077 (2004).
  Article CAS PubMed Google Scholar
• Moghrabi, A. et al. Results of the Dana–Farber Cancer Institute ALL Consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 26 Sep 2006 (doi:10.1182/blood-2006-06-027714 ).
• Bomgaars, L. et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J. Clin. Oncol. 22, 3916–3921 (2004).
  Article CAS PubMed Google Scholar
• Glantz, M. J. et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110–3116 (1999).
  Article CAS PubMed Google Scholar
• Jabbour, E. et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 5 Jan 2007 (doi:10.1182/blood-2006-08-043646).
• Offidani, M. et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukemia (ALL). Leuk. Lymphoma 46, 233–238 (2005).
  Article CAS PubMed Google Scholar
• Consoli, U. et al. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 88, 633–644 (1996).
  CAS PubMed Google Scholar
• Zou, Y., Priebe, W., Stephens, L. C. & Perez-Soler, R. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clin. Cancer Res. 1, 1369–1374 (1995).
  CAS PubMed Google Scholar
• Boman, N. L., Bally, M. B., Cullis, P. R., Mayer, L. D. & Webb, M. S. Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J. Liposome Res. 5, 523–541 (1995).
  Article CAS Google Scholar
• Gelmon, K. A. et al. Phase I study of liposomal vincristine. J. Clin. Oncol. 17, 697–705 (1999).
  Article CAS PubMed Google Scholar
• Thomas, D. A. et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106, 120–127 (2006).
  Article CAS PubMed Google Scholar
• Walling, J. From methotrexate to premetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest. New Drugs 24, 37–77 (2006).
  Article PubMed Google Scholar
• Sarris, A. H. et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J. Clin. Oncol. 20, 2876–2880 (2002).
  Article CAS PubMed Google Scholar
• O'Connor, O. et al. Pralatrexate (10-propargyl-10-deazaaminopterin (PDX), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity. Blood 106, 752a (2005).
  Google Scholar
• Wang, E. S., Connor, O., She, Y., Zelenetz, A. D., Sirotnak, F. M. & Moore, M. A. Activity of a novel anti-folate (PDX, 10-propargyl-10-deazaaminoptin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 44, 1027–1035 (2003).
  Article CAS PubMed Google Scholar
• Toner, L. E. et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin. Cancer Res. 12, 924–932 (2006).
  Article CAS PubMed Google Scholar
• Villela, L. R., Stanford, B. L. & Shah, S. R. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 26, 641–654 (2006).
  Article CAS PubMed Google Scholar
• Parker, W. B. et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerase by its 5′-triphosphate. Cancer Res. 51, 2386–2394 (1991).
  CAS PubMed Google Scholar
• Santana, V. M. et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J. Clin. Oncol. 9, 416–422 (1991).
  Article CAS PubMed Google Scholar
• Kornblau, S. M. et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/− cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10, 1563–1569 (1996).
  CAS PubMed Google Scholar
• Van Den Neste, E. et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann. Hematol. 76, 19–23 (1998).
  Article CAS PubMed Google Scholar
• Holowiecki, J. et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18, 989–997 (2004).
  Article CAS PubMed Google Scholar
• Vahdat, L. et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84, 3429–3434 (1994).
  CAS PubMed Google Scholar
• Warrell, R. P. Jr & Berman, E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4, 74–79 (1986).
  Article PubMed Google Scholar
• Montgomery, J. A., Shortnacy-Fowler, A. T., Clayton, S. D., Riordan, J. M. & Secrist, J. A. 3rd. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J. Med. Chem. 35, 397–401 (1992).
  Article CAS PubMed Google Scholar
• Avramis, V. I. & Plunkett, W. 2-fluoro-ATP: a toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenine. Biochem. Biophys. Res. Comm. 113, 35–43 (1983).
  Article CAS PubMed Google Scholar
• Kantarjian, H. M. et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 21, 1167–1173 (2003).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102, 2379–2386 (2003).
  Article CAS PubMed Google Scholar
• Jeha, S. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103, 784–789 (2004).
  Article CAS PubMed Google Scholar
• Jeha, S. et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 24, 1917–1923 (2006). References 49 and 50 report the paediatric trials that led to the accelerated clofarabine approval to treat children with ALL whose disease had not responded to or had relapsed following at least two prior regimens.
  Article CAS PubMed Google Scholar
• Giblett, E. R., Ammann, A. J., Wara, D. W., Sandman, R. & Diamond, L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1, 1010–1013 (1975).
  Article CAS PubMed Google Scholar
• Cohen, A., Lee, J. W. & Gelfand, E. W. Selective toxicity of deoxyguanosine and arabinosylguanine for T-leukemic cells. Blood 61, 660–666 (1983).
  CAS PubMed Google Scholar
• Reist, E. J. & Goodman, L. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry 3, 15–18 (1964).
  Article CAS PubMed Google Scholar
• Kurtzberg, J. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 23, 3396–3403 (2005).
  Article CAS PubMed Google Scholar
• Berg, S. L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 23, 3376–3382 (2005). References 54 and 55 report the trials that led to the accelerated nelarabine approval to treat adults and children with T-cell ALL and T-cell lymphoblastic lymphoma whose disease had not responded to or had relapsed following at least two prior regimens.
  Article CAS PubMed Google Scholar
• Miles, R. W., Tyler, P. C., Furneaux, R. H., Bagdassarian, C. K. & Schramm, V. L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37, 8615–8641 (1998).
  Article CAS PubMed Google Scholar
• Bantia, S. et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) — a novel potent and orally active immunosuppressive agent. Int. Immunopharm. 1, 1199–1210 (2001).
  Article CAS Google Scholar
• Gandhi, V. et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106, 4253–4260 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Schulz, H. et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematol. 89, 753–754 (2004).
  CAS Google Scholar
• Stasi, R., Pagano, A., Stipa, E. & Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952–957 (2001).
  Article CAS PubMed Google Scholar
• Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673–2677 (2002).
  Article PubMed Google Scholar
• Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).
  Article CAS PubMed Google Scholar
• Thomas, D. A. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106, 1569–1580 (2006).
  Article CAS PubMed Google Scholar
• Thomas, D. A. et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 102, 880a (2003).
• Jeha, S. et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108, 3302–3304 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Dillman, R. O. et al. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin. Exp. Med. 6, 1–12 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Leonard, J. P. et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10, 5327–5334 (2004).
  Article CAS PubMed Google Scholar
• Stein, R. et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10, 2868–2878 (2004).
  Article CAS PubMed Google Scholar
• Leonard, J. P. et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 5044–5051 (2005).
  Article CAS PubMed Google Scholar
• Linden, O. et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11, 5215–5222 (2005).
  Article CAS PubMed Google Scholar
• Uckun, F. M. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13–29 (1988).
  CAS PubMed Google Scholar
• Goulet, A. C. et al. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood 90, 2364–2375 (1997).
  CAS PubMed Google Scholar
• Stone, M. J. et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88, 1188–1197 (1996).
  CAS PubMed Google Scholar
• Bae, J., Martinson, J. A. & Klingemann, H. G. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin. Cancer Res. 11, 1629–1638 (2005).
  Article CAS PubMed Google Scholar
• Vallera, D. A. et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin. Cancer Res. 11, 3879–3888 (2005).
  Article CAS PubMed Google Scholar
• Gilleece, M. H. & Dexter, T. M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82, 807–812 (1993).
  CAS PubMed Google Scholar
• Piccaluga, P. P. et al. Anti-leukemic and anti-GVHD effects of Campath-1H in acute lymphoblatic leukemia relapsed after stem-cell transplantation. Leuk. Lymphoma 45, 731–733 (2004).
  Article CAS PubMed Google Scholar
• Laporte, J. P. et al. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 18, 1557–1558 (2004).
  Article CAS PubMed Google Scholar
• Tibes, R. et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106, 2645–2651 (2006).
  Article CAS PubMed Google Scholar
• Stock, W. et al. Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: a phase I/II study from the Cancer and Leukemia Group B (CALGB 10102). Blood 106, 46a (2005).
  Google Scholar
• Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).
  Article CAS PubMed Google Scholar
• Arceci, R. J. et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 106, 1183–1188 (2005).
  Article CAS PubMed Google Scholar
• Lo-Coco, F. et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104, 1995–1999 (2004).
  Article CAS PubMed Google Scholar
• Golay, J. et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128, 310–317 (2005).
  Article CAS PubMed Google Scholar
• Zwaan, C. M. et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 17, 468–470 (2003). References 84 and 85 describe in vitro, in vivo and clinical activity of gemtuzumab ozogamycin against CD33+ ALL.
  Article CAS PubMed Google Scholar
• Cotter, M., Rooney, S., O'Marcaigh, A. & Smith, O. P. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br. J. Haematol. 122, 687–688 (2003).
  Article PubMed Google Scholar
• Balduzzi, A. et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 17, 2247–2248 (2003).
  Article CAS PubMed Google Scholar
• Jedama, I. et al. Internalization and cell cycle-dependent killing of leukemia cells by gemtuzumab ozogamicin: rational for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18, 316–325 (2004).
  Article CAS Google Scholar
• Graux, C. et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genet. 36, 1084–1089 (2004).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
  Article CAS PubMed Google Scholar
• Champagne, M. A. et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104, 2655–2660 (2004).
  Article CAS PubMed Google Scholar
• Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396–4407 (2004).
  Article CAS PubMed Google Scholar
• Towatari, M. et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR–ABL-positive acute lymphoblastic leukemia. Blood 104, 3507–3512 (2004). References 90 and 91 report the activity of imatinib when used as a single agent in patients with relapsed Ph+ ALL. References 92 and 93 report on the safety and efficacy of administering imatinib in combination with intensive chemotherapy regimens in patients newly diagnosed with Ph+ ALL.
  Article CAS PubMed Google Scholar
• Rea, D. et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20, 400–403 (2006).
  Article CAS PubMed Google Scholar
• Lee, S. et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105, 3449–3457 (2005).
  Article CAS PubMed Google Scholar
• Wassmann, B. et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106, 458–463 (2005).
  Article CAS PubMed Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• O'Hare, T. et al. In vitro activity of Bcr–Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500–4505 (2005).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542–2551 (2006).
  Article PubMed Google Scholar
• Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N. Engl. J. Med. 354, 2531–2541 (2006).
  Article CAS PubMed Google Scholar
• Quintas-Cardama, A. et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogeneous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 21 Sep 2006 (doi:10.1182/blood-2006-07-035493).
• Giles, F. J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR–ABL mutation. Blood 21 Sep 2006 (doi:10.1182/blood-2006-05-025049).
• Lee, B. H. et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24, 7882–7892 (2005).
  Article CAS PubMed Google Scholar
• Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676 (2004).
  Article CAS PubMed Google Scholar
• Fiedler, W. et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105, 986–993 (2005).
  Article CAS PubMed Google Scholar
• Armstrong, S. A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173–183 (2003).
  Article CAS PubMed Google Scholar
• Torelli, G. F. et al. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br. J. Haematol. 130, 43–50 (2005).
  Article CAS PubMed Google Scholar
• Brown, P. et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105, 812–820 (2005).
  Article CAS PubMed Google Scholar
• Levis, M., Pham, R., Smith, B. D. & Small, D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104, 1145–1150 (2004).
  Article CAS PubMed Google Scholar
• Piloto, O. et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 66, 4843–4851 (2006).
  Article CAS PubMed Google Scholar
• Hoover, R. R., Mahon, F. X., Melo, J. V. & Daley, G. Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100, 1068–1071 (2002).
  Article CAS PubMed Google Scholar
• Kurzrock, R. et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22, 1287–1292 (2004).
  Article CAS PubMed Google Scholar
• Borthakur, G. et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106, 346–352 (2006).
  Article CAS PubMed Google Scholar
• Bueso-Ramos, C. et al. Protein expression of a triad of frequently methylated genes, p73, p57 Kip2, and p15, has prognostic value in adult acute lymphoblastic leukemia independently of its methylated status. J. Clin. Oncol. 23, 3932–3939 (2005).
  Article CAS PubMed Google Scholar
• Zheng, S. et al. Hypermethylation of the 5′ CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res. 64, 2000–2006 (2004).
  Article CAS PubMed Google Scholar
• Stam, R. W. et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 20, 264–271 (2006).
  Article CAS PubMed Google Scholar
• Christman, J. K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483–5495 (2002).
  Article CAS PubMed Google Scholar
• Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956–962 (2000).
  Article CAS PubMed Google Scholar
• Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350–358 (2003).
  Article CAS PubMed Google Scholar
• Messinger, Y, Reaman, G. H., EK, O. & Uckun, F. M. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Leuk. Lymphoma 33, 289–293 (1999).
  Article CAS PubMed Google Scholar
• Seiter, K. et al. Phase I study of temozolomide in relapsed/refractory acute leukemia. J. Clin. Oncol. 20, 3249–3253 (2002).
  Article CAS PubMed Google Scholar
• Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A. & Abrey, L. E. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 4, 39–43 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Sakajiri, S. et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 33, 53–61 (2005).
  Article CAS PubMed Google Scholar
• Byrd, J. C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959–967 (2005).
  Article CAS PubMed Google Scholar
• Inoue, S. et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11, S193–S206 (2004).
  Article CAS PubMed Google Scholar
• Nimmanapalli, R., Fuino, L, Stobaugh, C., Richon, V. & Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr–Abl-positive human acute leukemia cells. Blood 101, 3236–3239 (2003).
  Article CAS PubMed Google Scholar
• Batova, A. et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100, 3319–3324 (2002).
  Article CAS PubMed Google Scholar
• Cutts, S. M., Rephael, A., Nudelman, A., Hmelnitsky, I. & Phillips, D. R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 61, 8194–8202 (2001).
  CAS PubMed Google Scholar
• Avellino, R. et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106, 1400–1406 (2005).
  Article CAS PubMed Google Scholar
• Teachey, D. T. et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149–1155 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pear, W. S. et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283–2291 (1996).
  Article CAS PubMed Google Scholar
• Fekete, M. R., McBride, W. H. & Pajonk F. Anthracyclines, proteasome activity and multi-drug resistance. BMC Cancer 5, 114 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Cortes, J. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10, 3371–3376 (2004).
  Article CAS PubMed Google Scholar
• Sutheesophon, K. et al. Histone deacetylase inhibitor depsipetide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 115, 78–90 (2006).
  Article CAS PubMed Google Scholar
• Arguello, F. et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482–2490 (1998).
  CAS PubMed Google Scholar
• Almenara, J., Rosato, R. & Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16, 1331–1343 (2002).
  Article CAS PubMed Google Scholar
• Dasmahapatra, G., Almenara, J. A. & Grant, S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol. Pharmacol. 69, 288–298 (2006).
  CAS PubMed Google Scholar
• Rosato, R. R., Dai, Y., Almenara, J. A., Maggio, S. C. & Grant, S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 18, 1780–1788 (2004).
  Article CAS PubMed Google Scholar
• Yu, C., Krystal, G., Dent, P. & Grant, S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR–ABL-positive human leukemia cells. Clin. Cancer Res. 8, 2976–2984 (2002).
  CAS PubMed Google Scholar
• Karp, J. E. et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. 11, 8403–8412 (2005).
  Article CAS PubMed Google Scholar
• Banker, D. E. et al. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin. Cancer Res. 4, 3051–3062 (1998).
  CAS PubMed Google Scholar
• Campos, L. et al. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10, 434–438 (1996).
  CAS PubMed Google Scholar
• Hogarth, L. A. & Hall, A. G. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 93, 2671–2678 (1999).
  CAS PubMed Google Scholar
• Tauchi, T. et al. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR–ABL-positive cells. Clin. Cancer Res. 9, 4267–4273 (2003).
  CAS PubMed Google Scholar
• Marcucci, G. et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101, 425–432 (2003).
  Article CAS PubMed Google Scholar
• Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C. L. BCR–ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR–ABL chaperone heat shock protein 90. Blood 100, 3041–3044 (2002).
  Article CAS PubMed Google Scholar
• Crespo, M. et al. ZAP-70 expression in normal pro/pre B cells, mature B cells and in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 12, 726–734 (2006).
  Article CAS PubMed Google Scholar
• Rahmani, M. et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr–Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr–Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166–1176 (2005).
  Article CAS PubMed Google Scholar
• Pelicano, H. et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20, 610–619 (2006).
  Article CAS PubMed Google Scholar
• George, P. et al. Combination of the histone deacetylase inhibitor LBH589 and the HSP90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768–1776 (2005).
  Article CAS PubMed Google Scholar
• George, P. et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 64, 3645–3652 (2004).
  Article CAS PubMed Google Scholar
• Hawkins, L. M., Jayanthan, A. A. & Narendran, A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr–Abl status and imatinib mesylate sensitivity. Pediatr. Res. 57, 430–437 (2005).
  Article CAS PubMed Google Scholar
• Mesa, R. A. et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106, 318–327 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316–323 (2004). A comprehensive review of the genes and pathways involved in DNA-damage responses. Insights into the mechanisms involved in these response pathways might teach us new ways to more effectively treat leukaemia.
  Article CAS PubMed Google Scholar
• Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
  Article CAS PubMed Google Scholar
• Sawyers C. Targeted cancer therapy. Nature 432, 294–297 (2004).
  Article CAS PubMed Google Scholar
• Karagiannis, T. C. & El-Osta, A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. 12, 787–795 (2005).
  Article CAS PubMed Google Scholar
• Thomas, M., Gessner, A., Vornlocher, H. P., Hadwiger, P., Greil, J. & Heidenreich, O. Targeting MLL–AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106, 3559–3566 (2005). In vitro and severe combined immune deficiency mice studies indicating that targeted inhibition of MLL–AF4 fusion gene expression with short interfering RNAs might be an effective and highly specific treatment of this therapy-resistant leukaemia.
  Google Scholar
• Lang, P. et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood, 103, 3982–3985 (2004).
  Article CAS PubMed Google Scholar
• Blair, A., Goulden, N. J., Libri, N. A., Oakhill, A. & Pamphilon, D. H. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 19, 289–300 (2005).
  Article CAS PubMed Google Scholar
• Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376–383 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Sparreboom, A., Baker, S. D. & Verweij, J. Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J. Clin. Oncol. 23, 7765–7767 (2005).
  Article CAS PubMed Google Scholar
• Cheok, M. H. & Evans, W. E. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nature Rev. Cancer 6, 117–129 (2006). A comprehensive review of the role pharmacogenomics has in improving the therapeutic index of antileukaemic agents by facilitating appropriate dose individualization.
  Article CAS Google Scholar
• Rocha, J. C. et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105, 4752–4758 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, Q., Yang, W., Raimondi, S. C., Pui, C. H., Relling, M. V. & Evans, W. E. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nature Genet. 37, 878–882 (2005).
  Article CAS PubMed Google Scholar